TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients
Brief Summary: This study is designed to provide efficacy and safety data for certoparin in the prophylaxis of venous thromboembolism in immobilized, acutely ill medical patients.


Options:
A: Arm Label: Certoparin; Type: EXPERIMENTAL; Interventions: Drug: Certoparin | Arm Label: Unfractionated Heparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated Heparin | Intervention Type: DRUG; Name: Certoparin; Assigned to Arm(s): Certoparin | Intervention Type: DRUG; Name: Unfractionated Heparin; Assigned to Arm(s): Unfractionated Heparin
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939), Drug: Enoxaparin placebo | Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Rivaroxaban placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban placebo; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin placebo; Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939)
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Weight Gain During Pregnancy - a Randomized Controlled Trial of Intervention to Prevent Excessive Gestational Weight Gain.
Brief Summary: Excessive weight gain during pregnancy is associated with complications during delivery primarily due to macrosomia (large babies) but also with high levels of weight retention post pregnancy and thereby increased risk of future weight related health problems. The primary aim of this study is to evaluate the efficacy of an intervention consisting of; recurrent Motivational Interviewing (MI), prescription of physical activity and extended information on recommended weight gain during pregnancy in regards to preventing excessive gestational weight gain.


Options:
A: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: MOMs Healthy Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy MOMs Healthy Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Healthy MOMs Healthy Lifestyle Intervention; Assigned to Arm(s): MOMs Healthy Lifestyle Intervention
C: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotics | Arm Label: Probiotics + Dietary counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and probiotics | Arm Label: Dietary counseling + placebo; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary counselling and placebo | Arm Label: Prebiotics; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Prebiotics | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo capsules | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary counselling and placebo; Assigned to Arm(s): Dietary counseling + placebo | Intervention Type: BEHAVIORAL; Name: Dietary counselling and probiotics; Assigned to Arm(s): Probiotics + Dietary counseling | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo capsules; Assigned to Arm(s): Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotics; Assigned to Arm(s): Probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Prebiotics; Assigned to Arm(s): Prebiotics
D: Arm Label: control; Type: NO_INTERVENTION; Interventions: Behavioral: motivational intervention in pregnancy | Intervention Type: BEHAVIORAL; Name: motivational intervention in pregnancy; Assigned to Arm(s): control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for MS to get worse.

Other objectives of the study are to determine the safety and tolerability of BG00012, as well as the effect it may have on tests and evaluations used to assess MS. Additionally, glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012.


Options:
A: Arm Label: Teriflunomide 7 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg / 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo / Teriflunomide 14 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Teriflunomide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo / Teriflunomide 14 mg | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Placebo / Teriflunomide 14 mg, Teriflunomide 14 mg / 14 mg, Teriflunomide 7 mg / 14 mg
B: Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012, Drug: Placebo | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD); Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 240 mg Twice Daily (BID), Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate; Assigned to Arm(s): Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)
C: Intervention Type: DRUG; Name: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody); Assigned to Arm(s): N/A
D: Arm Label: Fingolimod (FTY720) 1.25 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Arm Label: Placebo/Fingolimod (FTY720); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Fingolimod (FTY720) 5.0 mg/day; Type: EXPERIMENTAL; Interventions: Drug: FTY720 | Intervention Type: DRUG; Name: FTY720; Assigned to Arm(s): Fingolimod (FTY720) 1.25 mg/day, Fingolimod (FTY720) 5.0 mg/day | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/Fingolimod (FTY720)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for MS to get worse.

Other objectives of the study are to determine the safety and tolerability of BG00012, as well as the effect it may have on tests and evaluations used to assess MS. Additionally, glatiramer acetate is being used to compare its benefits and risks with placebo and BG00012.


Options:
A: Arm Label: Natalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Natalizumab | Arm Label: Interferon-beta-1b; Type: EXPERIMENTAL; Interventions: Drug: interferon beta-1b | Intervention Type: DRUG; Name: interferon beta-1b; Assigned to Arm(s): Interferon-beta-1b | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Natalizumab
B: Arm Label: Teriflunomide 7 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Teriflunomide 14 mg; Type: EXPERIMENTAL; Interventions: Drug: Teriflunomide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for teriflunomide) | Intervention Type: DRUG; Name: Teriflunomide; Assigned to Arm(s): Teriflunomide 14 mg, Teriflunomide 7 mg | Intervention Type: DRUG; Name: Placebo (for teriflunomide); Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Ocrelizumab, Other: Placebo | Arm Label: Ocrelizumab 600 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ocrelizumab | Intervention Type: DRUG; Name: Ocrelizumab; Assigned to Arm(s): Ocrelizumab 600 mg, Placebo | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012, Drug: Placebo | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD); Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 240 mg Twice Daily (BID), Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate; Assigned to Arm(s): Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin and Oral Contraceptives in PCOS
Brief Summary: Background: PCOS is a common condition with a prevalence of 5-8 % in premenopausal women. More than 50% of PCOS patients are insulin resistant and have a diabetes risk 5-8 times higher than age- and weight-matched controls. Studies using insulin sensitizers in PCOS found increased insulin sensitivity and decreased insulin levels to be followed by decreased androgen levels and improved ovulatory function. No studies however, evaluated the long term effects of insulin sensitizing treatment.

Oral contraceptives normalize menstrual cycles and suppress androgen levels in PCOS, however no long-term studies evaluated the effects of combined treatment with metformin and oral contraceptives in PCOS.

Design: Randomized open study in 3\*30 PCOS patients. Patients are randomised to 24 months of treatment with 1: metformin, 2: metformin and oral contraceptives or 3: oral contraceptives.

Primary outcome measures: fasting insulin, AUC insulin. Secundary endpoints: BMI, WHR, LH, FSH, total and free-testosterone, c-peptid, urinary cortisol, AUC for insulin, glucose and c-peptid during OGTT.

Inclusioncriteria:

1. Irregular menses or anovulaty cycles
2. High free testosterone \> 0,035 nmol/l or hirsutism
3. PCO in vaginal US Criteria 1 and 2 OR 2 and 3.

Design:


Options:
A: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin, Behavioral: Lifestyle Intervention | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Lifestyle Intervention | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Metformin, Placebo
B: Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ethynyl-estradiol plus cyproterone acetate; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desorelle | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Desorelle | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Desorelle; Assigned to Arm(s): 2, 3
D: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral metformin | Arm Label: Oral contraceptive; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral contraceptive | Intervention Type: DRUG; Name: oral metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: oral contraceptive; Assigned to Arm(s): Oral contraceptive

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cholesterol and Pharmacogenetic Study
Brief Summary: The overall objective of the CAP study was to determine genetic influences on efficacy of simvastatin treatment with regard to LDL cholesterol reduction and changes in other markers of cardiovascular disease risk.


Options:
A: Arm Label: Pitavastatin 4 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Pitavastatin | Arm Label: Pravastatin 40 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin | Intervention Type: DRUG; Name: Pitavastatin; Assigned to Arm(s): Pitavastatin 4 mg QD | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Pravastatin 40 mg QD
B: Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
D: Arm Label: Fosinopril + Pravastatin; Type: EXPERIMENTAL; Interventions: Drug: Fosinopril, Drug: Pravastatin | Arm Label: Fosinopril + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fosinopril, Drug: Pravastatin Placebo | Arm Label: Pravastatin + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pravastatin, Drug: Fosinopril Placebo | Arm Label: Double Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Fosinopril Placebo, Drug: Pravastatin Placebo | Intervention Type: DRUG; Name: Fosinopril; Assigned to Arm(s): Fosinopril + Placebo, Fosinopril + Pravastatin | Intervention Type: DRUG; Name: Pravastatin; Assigned to Arm(s): Fosinopril + Pravastatin, Pravastatin + Placebo | Intervention Type: DRUG; Name: Fosinopril Placebo; Assigned to Arm(s): Double Placebo, Pravastatin + Placebo | Intervention Type: DRUG; Name: Pravastatin Placebo; Assigned to Arm(s): Double Placebo, Fosinopril + Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Stent Graft, Sirolimus Stent, and Bare Metal Stent Implanted in Patients With Acute Coronary Syndrome: Clinical and Angiographic Follow-up
Brief Summary: During the 6-month period 119 patients with acute coronary syndrome, were randomized to either stent graft group (n=40), sirolimus eluting stent group (n=39), or bare metal stent group (n=40). Demographic, angiographic and procedural characteristics were similar for all three groups. The incidence of 6-month major adverse coronary events were analysed.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: drug-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: bare-metal stent | Intervention Type: DEVICE; Name: drug-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: bare-metal stent; Assigned to Arm(s): 2
B: Intervention Type: PROCEDURE; Name: Distal protection and drug eluting stent; Assigned to Arm(s): N/A
C: Intervention Type: PROCEDURE; Name: Percutaneous Coronary Intervention; Assigned to Arm(s): N/A
D: Arm Label: Drug Eluting Absorbable Metal Scaffold; Type: EXPERIMENTAL; Interventions: Device: Percutaneous Coronary Intervention (DREAMS) stenting | Intervention Type: DEVICE; Name: Percutaneous Coronary Intervention (DREAMS) stenting; Assigned to Arm(s): Drug Eluting Absorbable Metal Scaffold

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-blind, Active-controlled (Enoxaparin 40 mg QD), Parallel-group, Multi-center Study to Evaluate the Safety and Efficacy of Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery (The ADVANCE - 2 Study)
Brief Summary: The purpose of this study is to learn whether apixaban prevents the development of blood clots in the leg (deep vein thrombosis) and lung (pulmonary embolism), which sometimes occur after knee replacement surgery, and to compare the efficacy of apixaban with that of enoxaparin (Lovenox®) in the prevention of these clots. The safety of apixaban will also be studied.


Options:
A: Intervention Type: DRUG; Name: EXANTA; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (BAY59-7939) | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Rivaroxaban (BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Arm 2
C: Arm Label: Apixaban, 2.5 mg BID + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Apixaban, Drug: Enoxaparin-matching placebo | Arm Label: Enoxaparin, 40 mg QD + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin, Drug: Apixaban-matching placebo | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin, 40 mg QD + Placebo | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban, 2.5 mg BID + Placebo | Intervention Type: DRUG; Name: Enoxaparin-matching placebo; Assigned to Arm(s): Apixaban, 2.5 mg BID + Placebo | Intervention Type: DRUG; Name: Apixaban-matching placebo; Assigned to Arm(s): Enoxaparin, 40 mg QD + Placebo
D: Arm Label: dabigatran etexilate 75 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: dabigatran etexilate 110 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate | Arm Label: enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: enoxaparin | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 75 mg | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 110 mg | Intervention Type: DRUG; Name: enoxaparin; Assigned to Arm(s): enoxaparin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo-Controlled Study of Acamprosate Added to Escitalopram and Behavioral Treatment in Major Depressive Disorder (MDD) With Comorbid Alcohol Abuse/Dependence
Brief Summary: This is a study about treatment for people who suffer from both major depression and alcohol abuse or dependence. The study will examine whether the addition of acamprosate to escitalopram and behavioral interventions will improve outcomes for this population.


Options:
A: Intervention Type: DRUG; Name: Ebixa (memantine hydrochloride); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Cipralex (escitalopram); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sertraline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: Paroxetine and naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: paroxetine, Drug: Naltrexone | Arm Label: paroxetine and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: paroxetine, Drug: Placebo | Arm Label: Desipramine and naltrexone; Type: ACTIVE_COMPARATOR; Interventions: Drug: desipramine, Drug: Naltrexone | Arm Label: Desipramine and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: desipramine, Drug: Placebo | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): Paroxetine and naltrexone, paroxetine and placebo | Intervention Type: DRUG; Name: desipramine; Assigned to Arm(s): Desipramine and naltrexone, Desipramine and placebo | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): Desipramine and naltrexone, Paroxetine and naltrexone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Desipramine and placebo, paroxetine and placebo
D: Arm Label: Escitalopram plus acamprosate; Type: EXPERIMENTAL; Interventions: Drug: acamprosate, Drug: escitalopram, Behavioral: Medical management | Arm Label: Escitalopram plus placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: escitalopram, Behavioral: Medical management, Drug: Placebo | Intervention Type: DRUG; Name: acamprosate; Assigned to Arm(s): Escitalopram plus acamprosate | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): Escitalopram plus acamprosate, Escitalopram plus placebo | Intervention Type: BEHAVIORAL; Name: Medical management; Assigned to Arm(s): Escitalopram plus acamprosate, Escitalopram plus placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Escitalopram plus placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-institutional Prospective Randomized Trial on the Assessment of Laparoscopic Surgery for Gastric Cancer
Brief Summary: The purpose of this study is to assess the usefulness of laparoscopic surgery for gastric cancer in comparison with open gastrectomy.


Options:
A: Intervention Type: PROCEDURE; Name: laparoscopy-assisted distal gastrectomy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: open distal gastrectomy; Assigned to Arm(s): N/A
B: Arm Label: Open Gastrectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Gastrectomy | Arm Label: Laparoscopic Gastrectomy; Type: EXPERIMENTAL; Interventions: Procedure: Laparoscopic Gastrectomy | Intervention Type: PROCEDURE; Name: Open Gastrectomy; Assigned to Arm(s): Open Gastrectomy | Intervention Type: PROCEDURE; Name: Laparoscopic Gastrectomy; Assigned to Arm(s): Laparoscopic Gastrectomy
C: Arm Label: Minimally-invasive Gastrectomy; Type: EXPERIMENTAL; Interventions: Procedure: Minimally-invasive gastrectomy | Arm Label: Open Gastrectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Open Gastrectomy | Intervention Type: PROCEDURE; Name: Minimally-invasive gastrectomy; Assigned to Arm(s): Minimally-invasive Gastrectomy | Intervention Type: PROCEDURE; Name: Open Gastrectomy; Assigned to Arm(s): Open Gastrectomy
D: Arm Label: open distal gastrectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: open distal gastrectomy | Arm Label: laparoscopy assisted distal gastrectomy; Type: EXPERIMENTAL; Interventions: Procedure: laparoscopy assisted distal gastrectomy | Intervention Type: PROCEDURE; Name: laparoscopy assisted distal gastrectomy; Assigned to Arm(s): laparoscopy assisted distal gastrectomy | Intervention Type: PROCEDURE; Name: open distal gastrectomy; Assigned to Arm(s): open distal gastrectomy

Answer: A